Skip to content
  • Clinical Studies
  • Pharma GMP
  • Pharma Tips
  • Stability Studies
  • Pharma Books
  • Schedule M

SOP Guide for Pharma

The Ultimate Resource for Pharmaceutical SOPs and Best Practices

  • Home
  • Job Safety Analysis (JSA)
    • Oral Dosage Forms (Tablets & Capsules)
    • Oral Liquid Dosage Forms (Syrups, Elixirs, Suspensions, Emulsions)
    • Powder and Granule Dosage Forms
    • Topical Dosage Forms (Creams, Ointments, Gels, Lotions, Pastes)
    • Transdermal Dosage Forms (Patches)
  • Standard Test Procedures (STP)
  • SOP – Blog Post
  • Toggle search form

BA-BE Studies: SOP for Plasma Separation and Aliquoting – V 2.0

Posted on By

BA-BE Studies: SOP for Plasma Separation and Aliquoting – V 2.0

Standard Operating Procedure for Plasma Separation and Aliquoting in BA/BE Studies

Department BA-BE Studies
SOP No. SOP/BA-BE/074/2025
Supersedes SOP/BA-BE/074/2022
Page No. Page 1 of 10
Issue Date 17/04/2025
Effective Date 20/04/2025
Review Date 17/04/2026

1. Purpose

To define the procedure for separation of plasma from whole blood and its subsequent aliquoting into labelled containers for storage and bioanalysis during Bioavailability/Bioequivalence (BA/BE) studies.

2. Scope

This SOP applies to all laboratory personnel involved in the post-centrifugation handling of blood samples for plasma separation and aliquoting at the clinical research facility or designated laboratory site.

3. Responsibilities

  • Lab Technician: Responsible for performing plasma separation and aliquoting as per protocol instructions.
  • Clinical Research Coordinator (CRC): Ensures sample labels are verified and matched with subject schedule and timepoint.
  • QA Personnel: Reviews log entries and verifies sample integrity and compliance during audits.
See also  BA-BE Studies: SOP for Monitoring Vital Signs During Clinical Phase - V 2.0

4. Accountability

The Bioanalytical Manager is accountable for ensuring plasma separation and aliquoting are conducted in accordance with regulatory requirements and analytical reliability standards.

5. Procedure

5.1 Pre-Separation Checks

  1. Ensure centrifuged tubes are:
    • Intact without hemolysis or leakage
    • Properly labelled
    • Handled using gloves to avoid contamination
  2. Verify each subject ID and time point using the sampling log.

5.2 Plasma Separation

  1. Use sterile disposable pipettes for each sample.
  2. Carefully aspirate the clear plasma layer without disturbing the buffy coat or red cells.
  3. Transfer plasma to pre-labelled cryovials or polypropylene tubes.

5.3 Aliquoting

  1. If multiple aliquots are required:
    • Equally divide the plasma into pre-labelled aliquot tubes (e.g., A1, A2, A3)
    • Label tubes with subject ID, timepoint, aliquot number, and date
  2. Place immediately in cold racks or freezer boxes based on specified storage conditions.
See also  BA-BE Studies: SOP for Preparing for GCP Inspections and Audit Readiness - V 2.0

5.4 Sample Volume Documentation

  1. Record the volume of plasma separated and aliquoted in Annexure-1: Plasma Separation Log.
  2. Note any discrepancies (e.g., low volume, hemolysis) and inform QA and the PI.

5.5 Sample Transfer and Storage

  1. Transfer samples to designated storage freezer:
    • -20°C for interim storage
    • -70°C for long-term storage, if specified
  2. Log freezer details and time of storage in Annexure-2: Aliquot Storage Log.

5.6 Deviation Handling

  1. Any cross-contamination, incorrect labelling, or sample damage must be documented in Annexure-3: Sample Handling Deviation Log.

6. Abbreviations

  • BA: Bioavailability
  • BE: Bioequivalence
  • CRC: Clinical Research Coordinator
  • QA: Quality Assurance
  • ID: Identification

7. Documents

  1. Plasma Separation Log – Annexure-1
  2. Aliquot Storage Log – Annexure-2
  3. Sample Handling Deviation Log – Annexure-3

8. References

  • ICH E6(R2) – Good Clinical Practice
  • FDA BA/BE Guidance for Industry
  • Study-Specific Protocol and Lab Manual
See also  BA-BE Studies: SOP for Study Initiation Checklist - V 2.0

9. SOP Version

Version: 2.0

10. Approval Section

Prepared By Checked By Approved By
Signature
Date
Name
Designation
Department

11. Annexures

Annexure-1: Plasma Separation Log

Subject ID Timepoint Volume (mL) Aliquot Nos. Initials Remarks
VOL-074 2h 4.5 A1, A2 Sunita Reddy —

Annexure-2: Aliquot Storage Log

Subject ID Aliquot No. Freezer ID Rack No. Storage Temp Time Handled By
VOL-074 A1 FZ-03 R2 -70°C 09:15 R. Pawar

Annexure-3: Sample Handling Deviation Log

Subject ID Issue Date Reported By Corrective Action Reviewed By
VOL-074X Hemolysis observed 17/04/2025 Nisha Verma Sample discarded, noted in CRF Dr. Arvind Shah

Revision History:

Revision Date Revision No. Details Reason Approved By
12/01/2022 1.0 Initial release Process standardization QA Head
17/04/2025 2.0 Incorporated detailed volume logging and deviation annexure Regulatory alignment QA Head
BA-BE Studies V 2.0 Tags:Absolute bioavailability, AUC (area under the curve), Bioavailability, Bioequivalence, Bioequivalence criteria, CDSCO bioequivalence norms, Clinical trial registration, Cmax (maximum concentration), Confidence interval %, Crossover study design, EMA bioequivalence requirements, Ethics committee approval, FDA bioequivalence guidelines, Generic drug approval, Good Clinical Practice (GCP), Good Laboratory Practice (GLP), Half-life (t½), ICH E(R) compliance, In vitro dissolution, In vivo studies, Informed consent process, Pharmacodynamics, Pharmacokinetics, Randomized controlled trial, Regulatory submission process, Relative bioavailability, Sample size calculation, Therapeutic equivalence, Tmax (time to maximum concentration), Washout period

Post navigation

Previous Post: Biosimilars: SOP for Southern Blot Analysis – V 2.0
Next Post: Aerosol: SOP for Analyzing Residual Cleaning Agents – V 2.0

Standard Operating Procedures V 1.0

  • Aerosols
  • Analytical Method Development
  • Bioequivalence Bioavailability Study
  • Capsule Formulation
  • Clinical Studies
  • Creams
  • Data Integrity
  • Dental Dosage Forms
  • Drug Discovery
  • Environment, Health and Safety
  • Formulation Development
  • Gels
  • Good Distribution Practice
  • Good Warehousing Practices
  • In-Process Control
  • Injectables
  • Liquid Orals
  • Liposome and Emulsion Formulations
  • Lotions
  • Lyophilized Products
  • Maintenance Dept.
  • Medical Devices
  • Metered-Dose Inhaler
  • Microbiology Testing
  • Nanoparticle Formulation
  • Nasal Spray Formulations
  • Nebulizers
  • Ocular (Eye) Dosage Forms
  • Ointments
  • Otic (Ear) Dosage Forms
  • Pharmacovigilance
  • Powder & Granules
  • Purchase Departments
  • Quality Assurance
  • Quality Control
  • Raw Material Stores
  • Regulatory Affairs
  • Tablet Manufacturing
  • Rectal Dosage Forms
  • Transdermal Patches
  • Vaginal Dosage Forms
  • Validations and Qualifications

Read SOPs in your Language:

 - 
Bengali
 - 
bn
English
 - 
en
Gujarati
 - 
gu
Hindi
 - 
hi
Malayalam
 - 
ml
Marathi
 - 
mr
Punjabi
 - 
pa
Tamil
 - 
ta
Telugu
 - 
te

NEW! Revised SOPs – V 2.0

  • Aerosols V 2.0
  • API Manufacturing V 2.0
  • BA-BE Studies V 2.0
  • Biosimilars V 2.0
  • Capsules V 2.0
  • Creams V 2.0
  • Ointments V 2.0
  • Raw Material Warehouse V 2.0
  • Tablet Manufacturing V2.0

New Publication: A must for All.

Copyright © 2025 SOP Guide for Pharma.

Powered by PressBook WordPress theme

Go to mobile version